Eli Lilly and Co
Change company Symbol lookup
Select an option...
LLY Eli Lilly and Co
NWFFX American Funds New World Fund® Class F-1
CARS Cars.com Inc
AHT Ashford Hospitality Trust Inc
AHII Fyolo Technology Corp
AHH-A Armada Hoffler Properties Inc
AHH Armada Hoffler Properties Inc
AHFD Active Health Foods Inc
AGSO AgriSolar Solutions Inc
AGS PlayAGS Inc
Go

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Closing Price
$154.17
Day's Change
1.70 (1.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
154.50
Day's Low
152.04
Volume
(Heavy Day)
Volume:
13,210,113

10-day average volume:
4,257,052
13,210,113

Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Valuation Ratios

Price/Earnings (TTM)
25.08x
Price/Sales (TTM)
6.43x
Price/Book (MRQ)
36.03x
Price/Cash Flow (TTM)
21.54x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

August 2020
Current Month
4.7M
Previous Month
4.2M
Percent of Float
0.49%
Days to Cover
2.1106 Days

Share Information

LLY is in a share class of common stock
Float
955.0M
Shares Outstanding
956.5M
Institutions Holding Shares
2,251
77.20%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • David A. RicksChmn.
  • Joshua L. SmileyCFO
  • Aarti ShahSr.VP
  • Daniel M. SkovronskySr.VP
  • Melissa Stapleton BarnesSr.VP

Address

Insider Trading

During the most recent quarter, 2M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.